SCHEMBL2192157

SCHEMBL2192157

O=C(Nc1ccc(-c2cnc(-c3ccc(NC(=O)[C@@H]4CCCN4C(=O)c4cccs4)cc3)o2)cc1)[C@@H]1CCCN1C(=O)c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
POLB P06746 1/20 0.54
LMNA P02545 4/20 0.52
APOBEC3A P31941 2/20 0.52
APOBEC3G Q9HC16 2/20 0.52
NPSR1 Q6W5P4 1/20 0.51
ALDH1A1 P00352 3/20 0.49
HPGD P15428 2/20 0.49
ALOX12 P18054 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PABPC1 P11940 1/20 0.43
EIF4H Q15056 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192758 0.88 MAPT (0.47) MAPTPOLBLMNAAPOBEC3AAPOBEC3G
SCHEMBL2193497 0.85 ALDH1A1 (0.43) MAPTPOLBLMNAAPOBEC3AAPOBEC3G
SCHEMBL2198220 0.85 MAPT (0.42) MAPTPOLBLMNAAPOBEC3AAPOBEC3G
SCHEMBL2192139 0.85 RHOC (0.44) MAPTALDH1A1HPGDSMN1; SMN2TSHR
SCHEMBL2196511 0.85 KMT2A (0.45) MAPTNPSR1ALDH1A1HPGDHTT
SCHEMBL13571673 0.84 ALDH1A1 (0.47) MAPTALDH1A1HPGDHTTSMN1; SMN2
SCHEMBL14664066 0.83 SMO (0.46) MAPTLMNAALDH1A1HPGDHTT
SCHEMBL2196787 0.83 ALDH1A1 (0.49) MAPTPOLBLMNAALDH1A1HPGD
SCHEMBL13570409 0.83 SMO (0.46) MAPTLMNAALDH1A1HPGDHTT
SCHEMBL2196987 0.83 HSD17B10 (0.50) MAPTPOLBLMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362020-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US claimed
EP-2519506-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-11-07 EP claimed
US-20110294819-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US claimed
WO-2011082077-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294819-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, GTF3C1 MAPT 2725/4885POLB 2039/4885LMNA 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.